Conjugated Linoleic Acid / Leucine Versus Metformin on Visceral Fat in Metabolic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

October 31, 2017

Conditions
Metabolic Syndrome
Interventions
DIETARY_SUPPLEMENT

Conjugated linoleic acid/Leucine

Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.

DRUG

Metformin

Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks

DIETARY_SUPPLEMENT

Placebo of ACL/Leucine

Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.

OTHER

Placebo of Metformin

homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks

All Listed Sponsors
lead

Centro Universitario de Ciencias de la Salud, Mexico

OTHER

NCT02629627 - Conjugated Linoleic Acid / Leucine Versus Metformin on Visceral Fat in Metabolic Syndrome | Biotech Hunter | Biotech Hunter